Kostas Biliouris
Stock Analyst at Oppenheimer
(1.12)
# 3,831
Out of 5,138 analysts
63
Total ratings
36%
Success rate
-15.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $22.40 | +176.79% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $21.31 | +134.63% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $359.26 | +30.82% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $77.21 | -9.34% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.52 | +163.16% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.71 | +115.63% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $72.60 | -0.83% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $16.42 | +204.51% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.56 | +349.64% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $11.87 | +321.23% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $3.90 | +771.79% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.69 | +905.92% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $7.61 | +425.62% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $22.11 | +307.06% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $8.80 | +1,263.64% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $32.05 | +77.85% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $76.26 | -51.48% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $55.07 | +81.59% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.99 | +376.19% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $54.21 | +80.78% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $22.40
Upside: +176.79%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $21.31
Upside: +134.63%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $359.26
Upside: +30.82%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $77.21
Upside: -9.34%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.52
Upside: +163.16%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.71
Upside: +115.63%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $72.60
Upside: -0.83%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $16.42
Upside: +204.51%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.56
Upside: +349.64%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $11.87
Upside: +321.23%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $3.90
Upside: +771.79%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.69
Upside: +905.92%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $7.61
Upside: +425.62%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $22.11
Upside: +307.06%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $8.80
Upside: +1,263.64%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $32.05
Upside: +77.85%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $76.26
Upside: -51.48%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $55.07
Upside: +81.59%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.99
Upside: +376.19%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $54.21
Upside: +80.78%